Document is current
Any future updates will be listed below
-
Authors
Hebebrand, Johannes https://orcid.org/0000-0001-5364-6073
Antel, Jochen https://orcid.org/0000-0002-7992-5684
Peters, Triinu https://orcid.org/0000-0002-7341-2802
-
Funding
Funding for this research was provided by:
Universitätsklinikum Essen
- License Information
-
More Information
Article History
Received: 8 August 2023
Accepted: 4 October 2023
First Online: 24 October 2023
Declarations
:
: Johannes Hebebrand and Jochen Antel declare that they were named as inventors in a patent application that the University of Duisburg-Essen filed on the use of leptin analogues for the treatment of depression and will be named on a patent application that the University of Duisburg-Essen is going to file on the use of leptin analogues for the treatment of atypical anorexia nervosa. Johannes Hebebrand and Jochen Antel declare that they were named as inventors in a patent application that the University of Duisburg-Essen had filed on the use of leptin analogues for treating anorexia nervosa and related conditions. Johannes Hebebrand received speaker’s honoraria from Amryt Pharmaceuticals in 2021 and Novo-Nordisk in 2022. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
